Clinical Trial Update: Efficacy and Safety of the Cryopreserved Formulation of OTL-101 in Subjects With ADA-SCID [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update on the cryopreserved formulation of OTL-101 for ADA-SCID assessing efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Combined Immunodeficiency Due to Ada Deficiency

Drugs mentioned

• OTL-101

Snippet

Sponsor: University of California, Los Angeles | Conditions: Severe Combined Immunodeficiency Due to ADA Deficiency | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-07-22